



Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	09/471,040
Filing Date	12/23/1999
First Named Inventor	TILSTAM, Ulf et al.
Group Art Unit	1623
Examiner Name	OWENS, Jr., Howard V.
Attorney Docket Number	SCH-1615-D01

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

*Handwritten signature*

6-10-05

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/471,040
		Filing Date	12/23/1999
		First Named Inventor	TILSTAM, Ulf et al.
		Group Art Unit	1623
		Examiner Name	OWENS, Jr., Howard V.
		Attorney Docket Number	SCH-1615-D01
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Ho	C1	Notice of Opposition to European Patent No. 1 047 704, Application No. 98965703.6, Mayne Pharma Pty, Ltd., Date of Mention 01/29/2003.	
Ho	C2	Declaration of Donald Corcoran, dated 10/27/2003.	
Ho	C3	Letter from Alltech Association Australia Pty, Ltd., dated 10/22/2003 with declaration attached from Dr. Phillip J. Anevski, dated 10/23/2003.	
Ho	C4	Letter from Boulton Tennant dated 10/29/2003.	
Ho	C5	The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241.	
Ho	C6	Exhibit C, Fludarabine Phosphate >99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950)	
Ho	C7	Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by Ion Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967).	
Ho	C8	In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54.	
Ho	C9	Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995).	
Ho	C10	Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998)	
Ho	C11	The MERCK Index, Twelfth Edition, 1996, <i>Fludarabine</i>	
Ho	C12	Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996).	
	C13	<del>U.S. Schering's Reply</del>	
Ho	C14	Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003.	
Ho	C15	Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003.	
Ho	C16	EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	
	C17	<del>PCT Report for App. No. PCT/EP98/07651, dated 1/27/00.</del>	

Examiner Signature	<i>Adrian</i>	Date Considered	6-10-05
--------------------	---------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.